Intracellular delivery of anti-dengue envelope monoclonal antibodies via PEG-PLGA nanoparticles suppresses viral replication and attenuates hepatocyte apoptosis
2
Issued Date
2026-04-01
Resource Type
ISSN
17732247
eISSN
25888943
Scopus ID
2-s2.0-105029285893
Journal Title
Journal of Drug Delivery Science and Technology
Volume
118
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Drug Delivery Science and Technology Vol.118 (2026)
Suggested Citation
Intrarakasem N., Kaewkarn S., Proykhunthod P., Songjaeng A., Avirutnun P., Prommool T., Puttikhunt C., Makeudom A., Morchang A., Tian X., Battaglia G., Patikarnmonthon N., Kraivong R. Intracellular delivery of anti-dengue envelope monoclonal antibodies via PEG-PLGA nanoparticles suppresses viral replication and attenuates hepatocyte apoptosis. Journal of Drug Delivery Science and Technology Vol.118 (2026). doi:10.1016/j.jddst.2026.108086 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/114953
Title
Intracellular delivery of anti-dengue envelope monoclonal antibodies via PEG-PLGA nanoparticles suppresses viral replication and attenuates hepatocyte apoptosis
Author's Affiliation
West China School of Medicine/West China Hospital of Sichuan University
Siriraj Hospital
Faculty of Science, Mahidol University
Thailand National Center for Genetic Engineering and Biotechnology
Mae Fah Luang University
Instituto de Bioingeniería de Cataluña
Mahidol University-University of Osaka Collaborative Research Center for Bioscience and Biotechnology
School of Medicine, Mae Fah Luang University
Siriraj Hospital
Faculty of Science, Mahidol University
Thailand National Center for Genetic Engineering and Biotechnology
Mae Fah Luang University
Instituto de Bioingeniería de Cataluña
Mahidol University-University of Osaka Collaborative Research Center for Bioscience and Biotechnology
School of Medicine, Mae Fah Luang University
Corresponding Author(s)
Other Contributor(s)
Abstract
Dengue virus (DENV) infection remains a major global health threat, with no specific antiviral treatment currently approved. Monoclonal antibody (mAb) therapy represents a promising strategy for viral inhibition; however, conventional antibodies are largely restricted to extracellular compartments and lack access to intracellular viral replication sites. In this study, we encapsulated a cross-reactive mAb targeting the DENV envelope protein (m513) into poly(ethylene glycol)- block -poly(lactide- co -glycolide) (PEG-PLGA) nanoparticles to facilitate intracellular delivery. When applied to immortalized hepatocyte-like cells (imHCs), the formulation demonstrated efficient cellular uptake, low cytotoxicity, and significantly reduced intracellular viral RNA and protein levels. The resulting formulation consisted of mAb-loaded PEG-PLGA nanoparticles (∼100 nm in diameter) with spherical morphology and an encapsulation efficiency of approximately 50%. Furthermore, nanoparticle treatment significantly reduced hepatocyte apoptosis in infected cells. Collectively, these findings demonstrate that nanoparticle-mediated intracellular antibody delivery can overcome a key limitation of conventional antibody therapy and represents a mechanistically distinct antiviral strategy for DENV and other intracellular viral infections.